List of Diagnostics Companies in Massachusetts - 70

At 100XBIO we strive to deliver 100x more data on antigen specificity of the T cells in the limited sample volume (blood, tumor, lymph nodes), and as the downstream -- confirming the cells' phenotype and cytokine expression. Looking for (1) early investments, (2) R&D partners, and (3) early academia, biotech and pharma clients. We are raising $500K of pre-seed investment, and raised over $200K.

At Activ Surgical, our mission is for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety. Having completed the world’s first autonomous robotic surgery of soft tissue in 2018, the company is focused on enhanced, real-time visualization capabilities for surgeons that combine advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make world-class surgery accessible for all.

Akrivis solutions cool equipment and deliver cleanroom conditions in modular buildings and cabins. Specialist units delivering exceptional performance, outstanding reliability, and ultra-low energy usage.

Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS).

Arrow Dx is combining Nanotechnology and Artificial Intelligence (AI) to create an inexpensive, sensitive test to screen early for non-alcoholic fatty liver disease (NAFLD). Our aim is to provide physicians with an alternative to liver biopsy which detects the disease too late. We are working to solve the lack of rapid, reliable, point-of-care, and inexpensive diagnostic devices by bring faster, inexpensive and mobile testing for many other applications that require a rapid response (e.g., epidemic/pandemics, public health crisis, early diagnosis for rising complex non-communicable diseases, testing in emergency rooms). Our technology makes it more affordable for smaller healthcare providers such as Physician Office Labs (~100,000 in the U.S.), independent physicians and public health workers to access diagnostics due to our significantly lower cost as well as our portable, small compact size. Finally, we are also working to create a test for COVID-19 as well as other viruses, initially quantifying the virus in wastewater to help public health authorities and later to detect it in biological samples from individuals and patients.

binx health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining "convenient care" for the modern consumer. binx is developing a suite of offerings that service healthcare needs where people live, work and shop. The Company's io® platform is designed to offer rapid PCR-based results, up to 24-plex, from sample-in-to-answer in about 30 minutes, greatly accelerating today's multiple day standard-of-care central lab testing paradigm. binx is driving solutions to take place in retail clinics, supermarkets, primary care offices, and at home. It does it through a suite of mobile and digital offerings. binx health investors includes financial investors, Johnson & Johnson Innovation, Novartis Venture Fund, LSP Venture Capital, BB Biotech, RMI Investments and Technology Venture Partners and strategic investors, Consort Medical (whose wholly owned subsidiary Bespak are the makers of the company's low-cost, proprietary multi-plex cartridges) and China-based Wondfo Biotech. binx health is a global company and has locations in Boston, MA and Bath UK. For further information visit www.mybinxhealth.com.

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient product for triage and monitoring of disease progression.

Cancer diagnostic

Ceretype Neuromedicine offers brain circuit profiles to stakeholders across the healthcare ecosystem. It is a services, platform, and insights company that can provide a groundbreaking biomarker engine for neurologic and psychiatric disease. Ceretype grew out of the desire of its physician-scientist cofounders to translate years of academic research in psychiatric neurobiology and imaging methods. It is a next-generation fMRI brain biomarker platform to improve drug discovery and patient care in neuropsychiatry.

Cognoptix is pioneering a new way to see Alzheimer's disease (AD): a low-cost, practical and non-invasive eye scan that detects beta-amyloid deposits in the lens. Amyloid is the earliest biomarker of AD, and our system can detect it years or decades before amyloid appears in the brain.

Collagen Medical is a healthcare company that specializes in medical products and services related to collagen.

Founded in 2015 in Salem, Mass., and operating out of its CLIA-certified laboratory and as an FDA-registered, ISO 13485-certified medical device manufacturer, Commonwealth Diagnostics International (CDI) helps providers identify and diagnose common sources of digestive distress and functional gastrointestinal ailments. CDI's expansive portfolio of non-invasive at-home hydrogen and methane breath tests supports the diagnosis and treatment of Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO), as well as fructose malabsorption, lactose malabsorption, and sucrose malabsorption. Focused on patient-centric principles, CDI breath tests are easy-to-use, quick, and safe for patients and support meaningful GI health outcomes by helping steer each practitioner's approach to dietary modification, homeopathic remedies, nutritional supplementation, immune support, high-quality probiotics, and additional testing.

At Dash Bio, we're revolutionizing clinical bioanalysis to expedite drug development. By leveraging AI and robotics, we deliver higher-quality assays with turnaround times up to 10x faster than the industry average for clinical trials and GLP studies. While AI startups have transformed drug discovery, the development phase remains bogged down by manual, labor-intensive processes. We're changing that narrative. Our tech-first products automate critical steps, reducing costs and time to market without compromising on quality. Our initial product line focuses on clinical bioanalysis—the testing of samples from clinical trial subjects. With a fresh perspective, we've built a modern platform where quality, automation, and regulation work seamlessly together. Why settle for traditional methods when you can invest in results? We're obsessed with enhancing customer experience and outcomes, constantly pushing boundaries to make processes better and faster.

The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

DeepHealth is RadNet's AI-powered health informatics subsidiary, created to empower breakthroughs in care delivery. The heart of its portfolio of solutions, the DeepHealth OS, is a cloud-native operating system that orchestrates all data to drive value across the enterprise. DeepHealth aims to elevate the role of the radiologist, beyond radiology and across the entire care pathway. It empowers all users across the care continuum with personalized workflows to make work easier and more meaningful. DeepHealth leverages advanced AI technologies in breast, lung, prostate, and brain health, as well as operational efficiencies to create end-to-end efficiency across the enterprise.

We manufacture Vision electrophysiology testing equipment for detecting eye diseases and sold mainly to hospital and eye doctors. Based in the USA, we create the leading solutions for electrophysiology for all your needs in hospitals, research and drug trials

Droplet has pioneered a platform to harvest and profile patient lymph through the routine collection of surgical drain fluid.

Dynocardia is a biomedical device development company committed to satisfying critical unmet needs to improve healthcare worldwide. ViTrack™, our lead diagnostic device, is powered our proprietary technology making it the only stand-alone, cuff-less device that allows for continuous, non-invasive blood pressure (cNIBP) measurement. Unlike conventional occlusive devices, ViTrack offers direct, beat-to-beat measurement of blood pressure that is wrist-wearable, mobile, and easy to use, with the accuracy of intra-arterial lines. ViTrack, with data-rich capability that includes heart rate, heart rhythm, and respiratory parameters in addition to blood pressure, enables early intervention prior to acute events.

Echosens is a healthcare technology company that specializes in non-invasive diagnostic tools for assessing liver health.

Elucid is a Boston-based medical technology company using histology-validated software to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid's CTA analysis equips physicians with critical information designed to enable precision medicine. Elucid is the first non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall. Elucid's unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs.

Empatica is an affective computing company, focused on human data analytics. We develop groundbreaking wearable devices with medical quality sensing. Our technology comprises a set of wristband, software running on smartphone and desktop computing, plus real time syncing with a cloud computing service.

Fortis Life Sciences® partners with diagnostics and life sciences companies to design, validate, and manufacture solutions to solve their complex development problems. Fortis’ tailored approach and end-to-end capabilities accelerate the work of its customers as they bring the next generation of medicines and diagnostics to market. Fortis serves a global customer base and has offices across North America including four R&D sites and three GMP and ISO 13485 compliant manufacturing facilities. Fortis offers a world-class portfolio of in-house manufactured and validated reagents and solutions through our industry-leading brands: Abcore, Arista Biologicals, Bethyl, Empirical Bioscience, IPOC, nanoComposix, and Vector Biolabs. We are a single partner with the: - Expertise to solve your most complex development problems. - Flexibility to design and validate solutions. - Scale to meet your manufacturing requirements.

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit us at www.FoundationMedicine.com or follow @FoundationATCG on Twitter. Community Guidelines: bit.ly/FMICommunityGuidelines

Today only 1 out if 4 cancer drugs prolongs life because we treat all the patients the same way. Genomic Expression's OneRNA™ test can save lives and make healthcare delivery more effective by sequencing RNA and linking RNA's to approved therapies and clinical trials.

GrapheneDx is designing adevice that willput the power of the highest performing diagnostics in the palm of your hand and the comfort of your home.

At Harbinger Health, our mission is to change the cancer paradigm by taking a proactive approach to cancer detection and prevention. We envision a future where cancer is no longer a life-altering event, but a routine health problem that can be addressed with early intervention. To achieve this, we have developed proprietary solutions for cancer pre-emption, starting with blood-based tests that can detect cancer before it even becomes visible. By identifying biological programs that are the root cause of cancer, we can enable early-stage and pre-disease identification, leading to truly personalized and effective cancer care for everyone. With Harbinger Health leading the way, we believe that a cancer-free future is not only possible but within reach, for everyone.

HelixBind is working to revolutionize care for invasive infections such as sepsis. Our novel diagnostic platform provides faster, more accurate, and more informative microbiology results direct from blood, assisting clinicians in identifying bloodstream infections and developing personalized antimicrobial interventions.. Our approach can improve outcomes, save lives, and reduce the spread of antimicrobial resistance.

We’re an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While we discover and develop groundbreaking products and services that benefit everyone, we are especially passionate about those that advance women’s health and well-being. This allows us to be a company that prospers, grows and empowers women to experience healthier lives. None of this would be possible without the talent, skills and aspirations of our employees. Their expertise and dedication to developing and sharing more robust, science-based certainty drives our increasingly global presence, as well as a pipeline that responds to the unmet health and wellness needs of women, families and communities. What powers our growth across Breast & Skeletal Health, Diagnostic Solutions, and GYN Surgical Solutions is also what differentiates us: the exceptional and clinically proven ability of our products to detect, diagnose and treat illnesses and other health conditions earlier and better. This clinical superiority creates high expectations, which we fulfill by always challenging ourselves to improve health through better technology, education and market access. Our goal is to minimize doubt and maximize the confidence our customers and their patients have in their decisions and diagnoses. We work toward this goal every day, always aware that in an increasingly complex and competitive global environment, we must continually earn the trust of our customers and their patients. By focusing on women’s health while still delivering health benefits to everyone, we are setting a new standard of excellence that is strengthened by purpose, driven by passion and brought to life by our promise of more certain early detection and better health outcomes. To view our community guidelines, visit: www.hologic.com/social-media

Kephera Diagnostics is a startup that aims to address the public health challenges of global infectious diseases with point of care assay technology.

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs. The company’s first product is the Lumicell Direct Visualization System, designed to provide real-time illumination of cancerous tissue within the breast cavity during the initial lumpectomy, potentially reducing repeat surgeries. Lumicell’s proprietary, pan-oncologic optical imaging agent is also being explored across a wide variety of solid tumor indications. The company aims to enhance the standard of care treatment by guiding the resection of additional cancer that may have otherwise been left behind.

MeMed is a leading med tech and bio-convergence company, having developed innovative diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes. Our mission is to translate the complex signals of the immune system into simple diagnostic insights that transform the way we treat infectious diseases and inflammatory disorders – at the right place and the right time.

Mercy BioAnalytics is on a mission to save lives and relieve suffering across the globe through the early detection of cancer. We have developed a novel liquid biopsy assay platform which interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling detection of cancer even in at the earliest stages. 

Whether it is partnering with clients to help with design for manufacturing on new programs or to support existing applications, Micron Products, Inc. is prepared to commit all resources necessary to find a solution. As a Full Service Supplier, each member of our manufacturing, product design, research and quality teams stand ready to work in collaboration with clients to meet any challenge. Micron Products, Inc. has been supplying the medical industry with world class quality medical components since 1978. Micron Products, Inc. is a wholly owned subsidiary of Micron Solutions Inc. (NYSE: MKT: MICR)

The Biosound® Therapy System The Biosound Therapy System integrates Biofeedback, Sound Frequency Healing, Music Therapy and Guided Imagery. The Biosound Therapy System consists of a vibrational platform constructed with...

myBiometry is a platform to remotely monitor and manage patients with chronic conditions using software and biomarker data generated from proprietary sensors. Our initial focus is asthma.

Myolex is disrupting how to measure muscle wasting (and treatment), caused by obesity drugs, aging, and sport injuries. Myolex® EIM is a patented device technology and SaaS data analytics platform that is built to disrupt skeletal muscle measurement by becoming the clinical and wellness standard to aid in the diagnosis and treatment of obesity drug and age-related muscle wasting. Myolex has developed the 1st quantitative, sensitive, painless, portable for home use muscle quality assessment device that is specifically designed to non-invasively, comprehensibly, and precisely detect and monitor single muscle wasting.

Nanopath Inc. is a molecular diagnostics company enabling high-quality molecular testing in minutes. The company is commercializing a first-in-class molecular diagnostic platform to enable scalable, point-of-care disease diagnosis.

Naveris has developed blood tests for cancers to enable early diagnosis in the general asymptomatic population, real time monitoring of response in patients undergoing treatment, and detection of cancer recurrence in patients in remission.

NeuroDex is developing a suite of blood-based biomarkers that can identify patients with synucleinopathies even in the context of different forms of dementia. This technology relies on NeuroDex’s recent advances in isolatingcell-specific extracellular vesicles (exosomes) from plasma and detecting protein markers of disease in the contents or on the surface of NDEs. Extracellular vesicles/exosomes are nano-sized (30-200nm) membrane vesicles released from all cell types in the body. While the biogenesis and biological function of extracellular vesicles are complex, it is clear that they carry protein, RNA, and lipids that reflect their cell of origin and thus can serve as a rich source of biomarkers.

Develops a diagnostics platform.

Overjet is the world-leader in dental AI. Founded by experts from MIT and Harvard University, Overjet builds artificial intelligence that helps dental organizations give patients the highest quality of care. Our FDA-cleared technology is the first objective standard for making oral health decisions — so that dentists can detect pathologies with precision and educate patients with confidence.

For 85 years, PerkinElmer has pushed the boundaries of science in our food, industrial, life science and environmental markets. In addition to innovative laboratory technologies, our OneSource services division delivers a highly trained, experienced, and collaborative team of service engineers with solutions scalable and customizable to serve laboratory needs. We’ve always pursued science with a clear purpose – to help our customers achieve theirs. Our expert team brings technology and intangibles, like creativity, empathy, diligence, and a spirit of collaboration, in equal measure, to fulfill our customers’ desire to work better, innovate better, and create better. PerkinElmer is a leading, global provider of technology and service solutions that help customers measure, quantify, detect, and report in ways that help ensure the quality, safety, and satisfaction of their products. Science with Purpose. Learn more at www.perkinelmer.com.

We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test to uncover actionable disease-defining transcriptional biology.  Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma.  By partnering with developers of new medicines and advancing our own diagnostic tests, we're working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that's precise to the biology of their disease.

PrecisionLife is the clinical-stage precision medicine company for complex chronic diseases. Creating better diagnostic tools and more personalized treatment options for patients with unmet medical needs. Our analytics and AI is unique in its understanding of causal disease biology. Identifying biomarkers to stratify patients by molecular mechanism of either their disease or drug response and link individuals to the drug targets, trials and treatments that will benefit them. With these insights we significantly increase the probability of success throughout the biopharma and healthcare value chain. Accelerating, informing and de-risking drug discovery and clinical development, building highly predictive diagnostics, and in launching more personalized and preventative medicines. To learn more, visit precisionlife.com.

Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

RT MicroDx is reshaping the healthcare landscape by developing accurate, affordable, at-home molecular testing solutions that empower individuals, alleviate financial distress, and contribute to healthier communities worldwide. Our readerless RT LAMP reaction, utilizing saliva samples, empowers individuals and families to take control of their health journey from the comfort of their homes. Leveraging our scalable testing platform, we are currently developing the first over-the-counter, molecular-based, at-home test for strep, the “RST,” offering a simplistic yet robust and inexpensive testing solution that only requires a saliva sample rather than a painful and invasive throat swab. With accuracy levels reaching 97% specificity and 99% sensitivity, our solutions transcend traditional at-home testing barriers, offering timely and reliable results.

SANO Diagnostics is pioneering a disposable, cost-effective point-of-care diagnostic platform with initial focus on human chronic wounds, such as diabetic foot ulcers and pressure ulcers. Measuring wound protease-related biochemistry to provide clinicians with more information on their patients'​ current wound status and progression, Sano's lead diagnostic is designed to help personalize treatment, promoting faster healing and significantly reducing treatment costs. The company is also in early stage development of a diagnostic for use in the equine market. Sano has won several awards/recognitions, including 1st place - Harvard Business School Boston Club – 1st place (judged by VC, angel, legal/service professionals), 1st place - Mass Medical Device Development Center (judged by Smith & Nephew, UMass Medical, legal/service professionals), Finalist - Harvard Business School New Venture Competition (judged by HBS alumni), 1st place Venture Forum 5 Minute Pitch, and 2015 Finalist, $50K Gold Award, MassChallenge (judged by investors, serial entrepreneurs, academic and for-profit execs).

We are biotech company located in the Boston area, with a mission to revolutionize non-invasive diagnostics. The systems we are developing allow monitoring cancer patients'​ progress, as well as looking very early into pregnancy to gain a complete genetic picture of the fetus, all with a simple blood test.

Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don’t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.

SeQure Dx, Inc. is applying genomics technologies for gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. Their GUIDE-seq and ONE-seq technologies enable identification of all potential off-target sites prior to initiating therapy, to allow comprehensive confirmation of actual edits.

Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home. Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that are transforming molecular diagnostics in clinical and non-clinical settings.

Sonde Health is a health technology company with a voice-enabled symptom detection and monitoring platform for chronic and mental health conditions. Our products are based on patented and proprietary, best-in-class technology developed by amazing people with advanced audio signal processing, speech science and machine learning backgrounds. We analyze over 4,000 vocal features that reflect changes in your voice caused by the changing physiology of your body due to symptoms of disease. Sonde's platform is designed with people's privacy in mind, and work on most smartphones people already own, preventing you from having to wear something new or add anything to your busy life.

Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity. We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and researchers to improve patient outcomes, and advance global health. For more information, please visit www.spear.bio or email info@spear.bio.

SpectraWAVE, located in Bedford, Mass., is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 18.2 million adults age 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events within two years. SpectraWAVE’s state of the art HyperVue™ Imaging System combines next generation DeepOCT™ images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab. The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended for the identification of patients and plaques at increased risk of major adverse cardiac events. For more information and complete indications for use, please visit www.spectrawave.com.

Advancing cerebrovascular care through groundbreaking neuro intravascular imaging and AI technologies.

Sunbird Bio is a leader in protein-based diagnostic tests, becoming the first company to overcome the challenge of accurately detecting and differentiating the specific proteins that aggregate, and therefore signal the presence of Alzheimer’s disease, with a simple blood draw. We are addressing the tremendous, growing need for more reliable and sensitive diagnostic tests to accelerate drug development and enhance patient care. Our pipeline of innovative, non-invasive technologies, such as our APEX technology, will empower researchers and clinicians with unparalleled insights not available from current tests.

Co-founded by MIT scientists in 2017 and headquartered in Cambridge, MA, Synlife's team is innovating new therapeutic and diagnostic platforms through bottom-up engineering of synthetic cells.

T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.

TellBio Inc. is a development stage biotechnology company with the goal to revolutionize the detection and treatment of cancer through its unique and proprietary circulating tumor cells (CTCs) technology and complementary therapeutics platform,

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

TransCode's lofty goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Our other preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, or PD-L1, and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. TransCode also has three cancer agnostic programs, TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. Until now, targeting biomarkers that are the primary drivers of cancer onset, progression and recurrence have been locked behind the challenge of delivery – cytosolic delivery to engage these known targets. TransCode believes it has overcome this barrier, opening the door to a broad array of cancer therapies -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery platform for the transport of targeted therapeutics to cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor indications with the goal of long-term treatment survival.

Transplant Genomics is a biotechnology company that focuses on improving organ transplant outcomes through noninvasive serial monitoring driven by genomics.

Universal Diagnostics S.A. (UDX) is a Spanish in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early when treatment options are more plentiful and survival rates are still high. UDX believes that the best way to fight against cancer is by detecting it early. The UDX diagnostic platform is designed to detect various cancer types, e.g. colorectal, prostate, liver, pancreatic lung, breast cancer (>50% of all new cancer cases p.a.) via one simple blood test. The assays rely on a curated set of proprietary methylation marker panels; a simple blood sample collected as part of a routine check-up, can be processed at a reference laboratory or hospital using standard equipment and then uploaded to the UDX Cloud for final algorithmic analysis. UDX's first marker panel is a colorectal cancer screening test. The test identifies individuals who need to be referred for colonoscopy. Colorectal cancer is the 3rd most frequent cancer and 2nd deadliest cancer worldwide. The challenge is that colorectal cancer is mostly detected in late stages, with significantly decreased survival rates (11% survival rate in stage IV vs. 85% survival rate in stage I). To develop the test and execute its R&D and operations, UDX partners with international research institutions, hospitals, universities, and biobanks around the globe.

Variantyx is a technology-driven precision medicine company providing state-of-the-art diagnostic solutions for the rare genetic disorders and reproductive genetics markets, and treatment optimization in oncology. Our unique, comprehensive testing platform uses whole genome sequencing to identify all major genetic changes from a single sample. The results empower patients and providers with information that can rapidly end the challenging diagnostic search, optimize treatment, and improve quality of life. We are a diverse, multinational company that embodies professionalism, transparency, tenacity, and respect. See more with us: www.variantyx.com/.

Verax Biomedical is a biomedical technology company that specializes in platelet bacterial contamination detection in cells and tissues intended for transfusion and transplantation.

VideaHealth is on mission to transform dentistry through artificial intelligence. Rooted in AI research conducted at Harvard and MIT, VideaHealth’s FDA-cleared dental AI platform is proven to increase diagnostic accuracy, grow treatment plan values, and improve case acceptance rates. With the largest and most diverse data set in the market, VideaHealth is the partner of choice for the nation's leading DSOs - and is trusted by dentists, hygienists and patients. Backed by leading venture capital firms Spark Capital, Zetta Venture Partners and Pillar VC, VideaHealth is headquartered in Boston.